UK Medicines Information
Imiquimod (Zyclara®) is accepted for restricted use within NHS Scotland
Information type:
Drug best practice guidance
Source:
Scottish Medicines Consortium
Specialities:
Skin disorders
Summary
Imiquimod (Zyclara) is approved for use for clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
UKMi comment
The SMC have restricted use to the treatment of large field actinic keratosis (>25cm2).
Related links: